Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
perphenazine + amitriptyline
- Development stage
- Approved
- Lead developer
- Bayer
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**Perphenazine + amitriptyline** is a fixed-dose oral combination of a *typical antipsychotic* (perphenazine) and a *tricyclic antidepressant* (amitriptyline). It is indicated for the treatment of moderate to severe depression with anxiety or agitation, depression and anxiety associated with chronic physical disease, and schizophrenia with prominent depressive symptoms. **Amitriptyline** works predominantly by inhibiting the reuptake of serotonin and norepinephrine in the central nervous system, increasing their availability. **Perphenazine** acts primarily as a dopamine D2 receptor antagonist, reducing dopaminergic neurotransmission related to psychotic symptoms. The combination addresses co-occurring mood and psychotic or anxiety symptoms. The product has been marketed under several brand names and is manufactured in the US by Mylan Pharmaceuticals and Remedy Repack[1][3][5][7].
- Brand names
- EtrafonTriavilDuo-VilTriptafen
- Other names
- perphenazine/amitriptylineamitriptyline/perphenazine
02
Targets
SERT (Sodium-dependent serotonin transporter)HRH1 (Histamine H1 Receptor)M1 (Muscarinic acetylcholine receptor M1)ADRA1A (α1A)HTR2A (Serotonin receptor 5-HT2A)HTR2C (5-hydroxytryptamine 2C receptor)DRD2 (Dopamine D2 Receptor)DRD3 (Dopamine receptor D3)NET (Norepinephrine Transporter)CHRM3 (M3)
Beyond the preview
Go deeper on perphenazine + amitriptyline.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on perphenazine + amitriptyline.